Key result
Chronic Chagas cardiomyopathy treatments rely on extrapolated evidence rather than disease-specific trial data.
Why the study?
Chagas disease has become globalized, making the detection and treatment of chronic manifestations such as chronic Chagas cardiomyopathy a relevant issue as many treatments are extrapolations of existing evidence.
This review highlights the current diagnostic and therapeutic landscape for chronic Chagas cardiomyopathy, emphasizing that most pharmacological treatments are extrapolated from general heart failure guidelines and underscoring the need for dedicated trials in this population.
Extrapolated HF therapies warrant cautious use in chronic Chagas cardiomyopathy; leaves open the need for dedicated randomized trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Martins et al. (2023) conducted a review in Chronic Chagas cardiomyopathy. Pharmacological and non-pharmacological treatments for chronic Chagas cardiomyopathy remain largely based on extrapolations of existing evidence rather than disease-specific trial data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: